Galli SJ, et al.: Mast cells in the development of adaptive immune responses. Nat Immunol Rev. 6: 135-42, 2005.
Lee DM, et al.: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 297: 1689-92, 2002.
Shin K, et al.: Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol. 182: 647-56, 2009.
Ruoss SJ, et al.: Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest. 88: 493–499, 1991.
Garbuzenko E, et al.: Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy. 32: 237–246, 2002.
Walker M, et al.: Mast cells and their degranulation in the Tsk mouse model of scleroderma. Proc Soc Exp Biol Med. 180: 323–328, 1985.
McNeil HP, et al.: The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum. 58: 2338-46, 2008.
Stevens RL, et al.: Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev. 217: 155-67, 2007.
Nigrovic PA, et al.: Synovial mast cells: role in acute and chronic arthritis. Immunol Rev. 217: 19-37, 2007.
Green MC, et al.: Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82: 493–512, 1976.
Menton DN, et al.: The ultrastructure of collagen in the dermis of tight-skin (Tsk) mutant mice. J Invest Dermatol 74:139–147, 1980.
Walker M, et al.: Mast cells and their degranulation in the Tsk mouse model of scleroderma. Proc Soc Exp Biol Med 180: 323–328, 1985.
Walker MA, et al.: Inhibition of fibrosis in TSK mice by blocking mast cell degranulation. J Rheumatol 14: 299–301, 1987.
Walker M, et al.: Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol 17: 57–59, 1990.
Everett ET, et al.: The role of mast cells in the development of skin fibrosis in tight-skin mutant mice. Comp Biochem Physiol A Physiol 110: 159–165, 1995.
Wang HW, et al.: Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 14: 295–302, 2005.
Yamamoto T, et al.: Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112: 456–462, 1999.
Yamamoto T, et al.: Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. J Rheumatol 26: 2628–2634, 1999.
Jaffee BD, et al.: Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 77: 1–12, 1983.
Claman HN, et al.: Chronic graftversus- host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 94: 73–84, 1985.
Levi-Schaffer F, et al.: Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant 19: 823–828, 1997.
Steen VD: Scleroderma renal crisis. Rheum Dis Clin North Am 29: 315-333, 2003.
Badesch DB, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med, 132: 425-434, 2000.
Guillevin L, et al.: Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis, 65: 392, 2006.
Tashkin DP, et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med, 354: 2655-2666, 2006.
Distler JH, et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56: 311-22, 2007.
Akhmetshina A, et al.: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 60: 219-24, 2009.
Chung L, et al.: Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum.